Elsevier announces standards-ready clinical decision support enhancements in Gold Standard Drug Database to enable interoperability and transparency in healthcare applications

Elsevier announced new clinical decision support (CDS) enhancements in its Gold Standard Drug Database (GSDD) that enable customers to use industry-standard identifiers across core medication safety checks and provide transparent responses when no alert is triggered. The updates aim to help healthcare technology companies and pharmacy organizations integrate CDS faster, reduce manual exception queues, and operate confidently in multi‑vendor ecosystems.

GSDD now accepts RxNorm (RxCUIs) ICD‑10-CM, ICD-10-PCS and SNOMED CT as inputs for drug interaction, duplicate therapy and drug–disease safety checks, including contraindications and precautions. New input validation delivers explicit “reason responses” when no alert is produced, giving product and engineering teams clear, actionable insight into CDS behavior.

Elsevier is also enhancing Drug-Allergy safety checking, made available in March 2026, with support for RxCUI and SNOMED CT allergen inputs. A new allergy catalogue will be introduced to support clinician, patient, and consumer documentation, RxNorm and SNOMED CT drug substances, brands, drug classes, dietary and environmental allergens.

Rhett Alden, Chief Technology Officer at Elsevier said “These standards-ready capabilities reflect our commitment to helping customers meet interoperability requirements while improving operational efficiency. RxNorm, ICD-10, and SNOMED CT are cornerstone clinical terminologies that make interoperability possible by ensuring different systems mean the same thing when they exchange data. By utilizing these industry standard identifiers and providing transparent responses, we’re supporting safer, faster workflows without requiring our valued customers to rearchitect their systems. Transparency matters in clinical decision support – clear responses reduce unnecessary exception reviews and accelerate troubleshooting. Combined with standards-based inputs, customers can implement CDS more quickly and trust the results they see.”

The enhancements reinforce Elsevier’s clinical depth and ongoing content maintenance, aligning with the company’s broader focus on delivering safety, efficiency, and scalability across the health information ecosystem.

About Gold Standard Drug Database

Elsevier’s Gold Standard Drug Database (GSDD) provides normalized, clinically curated medication product and semantic data to help organizations standardize drug information and support medication management, clinical decision support, and interoperability across healthcare workflows. Maintained by clinical pharmacists and subject‑matter experts, GSDD integrates via flexible data feeds and APIs and is used by health systems, payers, pharmacies, and health‑technology companies.

エルゼビアについて

エルゼビアは、先端情報と意思決定を支援しています。1世紀以上にわたり、人類の進歩のため先端科学とヘルスケアの進歩に貢献してきました。私たちは、170か国にわたるアカデミアや企業の研究コミュニティ、医師、看護師、未来の医療従事者、教育者の皆さまの重要な活動をサポートしています。これは、信頼できるエビデンスに基づく科学・医療コンテンツと高度なAI技術を組み合わせた革新的なソリューションにより知見の集積や重要な意思決定を支援することで実現しています。また、私たちは、これらの価値を製品や企業文化に組み込み、コミュニティとの協働を通じて、インクルージョンと持続可能性を推進しています。エルゼビア財団opens in new tab/windowは、世界中の研究と医療のパートナーシップを支援しています。

エルゼビアは、専門家およびビジネス向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Groupopens in new tab/windowの一事業を担っています。詳細につきましては、www.elsevier.comまたはソーシャルメディア@Elsevier Connectをご覧ください。